- Home
- JSPR vs RZLT Comparison
JSPR vs RZLT Comparison
Compare JSPR & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- RZLT
- Stock Information
- Founded
- JSPR 2018
- RZLT 2010
- Country
- JSPR United States
- RZLT United States
- Employees
- JSPR N/A
- RZLT N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- RZLT Health Care
- Exchange
- JSPR Nasdaq
- RZLT Nasdaq
- Market Cap
- JSPR 325.7M
- RZLT 292.0M
- IPO Year
- JSPR N/A
- RZLT N/A
- Fundamental
- Price
- JSPR $21.71
- RZLT $4.41
- Analyst Decision
- JSPR Strong Buy
- RZLT Strong Buy
- Analyst Count
- JSPR 11
- RZLT 8
- Target Price
- JSPR $73.38
- RZLT $11.63
- AVG Volume (30 Days)
- JSPR 184.2K
- RZLT 373.9K
- Earning Date
- JSPR 11-07-2024
- RZLT 02-11-2025
- Dividend Yield
- JSPR N/A
- RZLT N/A
- EPS Growth
- JSPR N/A
- RZLT N/A
- EPS
- JSPR N/A
- RZLT N/A
- Revenue
- JSPR N/A
- RZLT N/A
- Revenue This Year
- JSPR N/A
- RZLT N/A
- Revenue Next Year
- JSPR N/A
- RZLT N/A
- P/E Ratio
- JSPR N/A
- RZLT N/A
- Revenue Growth
- JSPR N/A
- RZLT N/A
- 52 Week Low
- JSPR $5.02
- RZLT $0.88
- 52 Week High
- JSPR $31.01
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- JSPR 49.34
- RZLT 38.76
- Support Level
- JSPR $20.77
- RZLT $4.07
- Resistance Level
- JSPR $23.11
- RZLT $4.64
- Average True Range (ATR)
- JSPR 1.67
- RZLT 0.32
- MACD
- JSPR -0.08
- RZLT -0.04
- Stochastic Oscillator
- JSPR 51.34
- RZLT 24.29
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.